Impact of Radiation Therapy Facility Volume on Survival among Patients with Cancer
Leila T. Tchelebi,Biyi Shen,Niraj J. Gusani,Ming Wang,Nicholas G. Zaorsky
DOI: https://doi.org/10.1016/j.ijrobp.2020.02.622
2020-01-01
Abstract:Receiving radiation therapy at a high-volume center has been shown to improve survival for certain cancer types. Studies have been heterogeneous and disparate in their patient inclusion and definition of facility volume, and only a subset of cancer types have been evaluated. The purpose of the present work is to uniformly evaluate the impact of radiation therapy facility volume on survival in patients with cancer. The National Cancer Database (NCDB) was queried for patients diagnosed with the 20 non-metastatic cancers most commonly treated with radiation therapy and valid radiation start date, from 2004-2013. Facilities were stratified by four volume categories, each including 25% of patients: low (765 facilities, each treating < 150 pts/year), intermediate (297 facilities, each treating 150-258 pts/year), high (176 facilities, each treating 259-433 pts/year), and very high (92 facilities, each treating > 433 pts/year). Kaplan-Meier curves of five-year post-radiotherapy survival, stratified by facility volume categories, were displayed for each type of cancer with log-rank tests for group comparisons. Cox proportional hazard models with Bonferroni correction were used to further evaluate the effects of facility volume on five-year post-radiation survival adjusted for age, sex, race, insurance status, disease stage, urban vs rural setting, income, comorbidity, facility type, surgery, chemotherapy, immunotherapy, and distance traveled to facility. A total of 2,335,126 patients who received radiation were included (average 62.6 years, range: 18-90) from 1,330facilities; of these, 960,428 (41.1%) had breast, 271,693 (11.6%) had lung, and 231,068 (9.9%) had prostate cancer. The majority of patients were female (62.0%), white (85.9%), privately insured (46.2%). For the majority of cancers, risk of death for patients receiving radiation therapy at very high volume facilities was 92% of that for those treated at low volume facilities. Hazard ratios were lowest (very high volume vs low) for cancer of the uterus (HR = 0.57, 95% CI 0.42- 0.77; high volume = >3 pts/year), prostate (HR = 0.71, 95% CI 0.66- 0.78; high volume = >53 pts/year), anus (HR = 0.72, 95% CI 0.65-0.81; high volume = >5 pts/year;), rectum (HR = 0.90, 95% CI 0.83, 0.97; high volume = >12 pts/year), hepatobiliary tract (HR = 0.74, 95% CI 0.56-0.98; high volume = >8 pts/year), melanoma (HR = 0.77, 95% CI 0.63-0.95; high volume = >7 pts/year), and breast (HR = 0.81, 95% CI 0.78-0.84; high volume = >170 pts/year). The differences were smallest or insignificant for cancers of the testis, cervix, bladder, vulva, and lung. For the majority of cancers, patients treated at higher volume radiation therapy facilities have improved overall survival as compared to those treated at low volume centers, although the magnitude of difference varies greatly and is cancer-specific.